Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:
“One of the most important potential applications of ctDNA may be detecting recurrence before it becomes evident on imaging; however, its true clinical value will become clear only when it is shown that acting on this early signal improves patient outcomes.
In a study of 119 patients with resected NSCLC, longitudinal monitoring detected MRD in 48.1% of recurrences and became positive a median of 6.53 months before imaging. The key question is whether acting on this early signal improves patient outcomes.”
Title: Perioperative ctDNA dynamics predict outcomes in resectable NSCLC using an ultrasensitive and cost-effective assay
Authors: Bao-Xiao Wang, Hao Jiang, Wei Ou, Teng-Fei Zhu, Jian Li, Fei Liu, Xiao-Xue Ma, Bo-Ying Zheng, Si-Ao Jiang, Ning Li, Bin-Bin Zhang
Read the Full Article
You can also read: ‘ctDNA and MRD in NSCLC: Emerging Clinical Applications in the Immunotherapy Era‘
